RSS   Newsletter   Contact   Advertise with us
Post Online Media

Silence Therapeutics appoints David Ellam as CFO

Silence TherapeuticsSilence Therapeutics, a biotechnology company, announced that David Ellam will become chief financial officer and a director from July 18, 2016.

Mr. Ellam has previously occupied several senior finance roles within both US & UK publicly owned life science companies, most recently as Senior EUMEA Finance Director at BioMarin Pharmaceuticals Inc. from 2010 to 2016, as CFO of Plethora Solutions Plc (2008-2009) and as Group Financial Controller at Ark Therapeutics Plc (2001-2008).

READ MORE Silence Therapeutics appoints Alistair Gray as director

Mr. Ellam is a Chartered Accountant.

What to read next

 LATEST MOVES FROM United Kingdom 

More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy